Try our Advanced Search for more refined results

Daiichi Sankyo Company, Limited v. Seagen Inc.

Track this case

Case Number:

1:19-cv-02087

Court:

Delaware

Nature of Suit:

Contract: Other

Judge:

Leonard P. Stark

Firms

Companies

Sectors & Industries:

  1. May 01, 2020

    Daiichi Told Cancer Drug Patent Fight Must Be Arbitrated

    An arbitrator has concluded that a dispute between Daiichi Sankyo Co. Ltd. and a U.S. biotechnology company over cancer drug patents should be arbitrated, saying he was obligated to do so since it was not obvious whether the dispute fell under an exclusion in the parties' agreement.

  2. April 09, 2020

    Daiichi Says Court Should Decide Drug Patent Fight Venue

    Daiichi Sankyo Co. Ltd. told a Delaware court Wednesday that it must decide whether its dispute with a U.S. biotechnology company over cancer drug patents must be arbitrated or litigated, saying a magistrate judge created a "new bright-line rule" when she recommended referring the matter to an arbitrator.

  3. March 16, 2020

    Tribunal Awaits Judge's Nod On Daiichi Drug Patent Fight

    An arbitrator weighing whether he can adjudicate biotechnology company Seattle Genetics Inc.'s dispute with Daiichi Sankyo Co. Ltd. over cancer drug patents will wait for recommendations from a Delaware court before deciding, according to the Japanese pharmaceutical company.